Exact Sciences
EXAS
$63.24
Share price
-0.46%
Change (1 day)
-4.49%
Change (1 year)
Categories
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer.
Exact Sciences (EXAS) - Total debt
Total debt on the balance sheet as of December 2023 : $2.55 B
According to Exact Sciences's latest financial reports the company's total debt is $2.55 B. A company’s total debt is the sum of all current and non-current debts.
Exact Sciences - Total debt on balance sheet (from 2009 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-12-31 | $2.55 B | 4.41% |
| 2022-12-31 | $2.44 B | 2.72% |
| 2021-12-31 | $2.38 B | 2.21% |
| 2020-12-31 | $2.33 B | 144.04% |
| 2019-12-31 | $0.95 B | 38.56% |
| 2018-12-31 | $0.68 B | 15385.31% |
| 2017-12-31 | $4.45 M | -18.97% |
| 2016-12-31 | $5.49 M | -8.69% |
| 2015-12-31 | $6.01 M | 102.29% |
| 2014-12-31 | $2.97 M | -31.88% |
| 2013-12-31 | $4.36 M | 113.6% |
| 2012-12-31 | $2.04 M | 104.4% |
| 2011-12-31 | $1 M | 0% |
| 2010-12-31 | $1 M | -49.7% |
| 2009-12-31 | $1.98 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $20.36 B | 697.23% | 🇫🇷 France |
 Veracyte VCYT | $12.63 M | -99.51% | 🇺🇸 USA |
 Antares Pharma ATRS | N/A | N/A | 🇺🇸 USA |
 Myriad Genetics MYGN | $0.15 B | -94.05% | 🇺🇸 USA |
 Biocept
BIOC | $11.59 M | -99.55% | 🇺🇸 USA |